Optimizing the Care of Patients With Colorectal Cancer in Clinical Practice

Presented by Mary B. Morgan,(1) MSN, ANP-BC, AOCN®, and Tammy Triglianos,(2) DNP, ANP-BC, AOCNP®

At JADPRO Live 2023, presenters emphasized the importance of increasing colorectal cancer screening in high-risk groups, reviewed guidelines in the adjuvant and metastatic setting, and outlined clinical and molecular profiles to consider...

Hyperammonemia Secondary to 5-Fluorouracil

Ashley Scott,(1,2) RN, BSN, OCN®, Sreenivas V. Rao,(2) MD, and Mary Lou Affronti,(1) DNP, RN, MHSc, ANP, FAAN

5-fluorouracil (5-FU) is one of the most common adjuvant antineoplastic agents used in the treatment of localized and metastatic colon cancer. Frequent side effects of 5-FU include myelosuppression, mucositis, nausea, vomiting, and diarr...

Managing the Patient With Multiple Primary Tumors

Presented by Holly Chitwood, DNP, APRN, FNP, AGACNP, and Tamara Carey, MSN, APRN, FNP

Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy strategy that covers both cancer types withou...

Improving Outcomes for Patients With Metastatic Colorectal Cancer: Challenges and Strategies

Presented by Leslie A. Swanson,(1) ARNP, and Kathleen Boyle,(2) PA-C

At JADPRO Live 2019, Leslie A. Swanson, ARNP, and Kathleen Boyle,PA-C, reviewed guideline-concordant molecular testing and therapy in patients with metastatic colorectal cancer (mCRC), the clinical significance of emerging data for exist...

Enhanced Recovery After Surgery

Lisa Parks,(1) MS, RN, CNP, Meghan Routt,(2) MSN, ANP/GNP-BC, AOCNP®, and Allison De Villiers,(1) MSN, RN, OCN®, ACNS-BC

Abstract Enhanced recovery after surgery (ERAS) is a multimodal perioperative care pathway designed to achieve early recovery for patients undergoing major surgical procedures. Meta-analyses, randomized controlled trials, and large pros...

Hereditary Aspects of Colorectal Cancer: Mismatch Repair Genes Drive Lynch Syndrome

Lynch syndrome is the most common inherited form of colorectal cancer, affecting approximately 1 in 279 individuals, or 1.2 million people in the United States. It's also associated with a predisposition to endometrial, ovarian, and stom...

Liver Resection in Patients With Synchronous Colorectal Liver and Lung Metastases

Assessment of Overall Survival Benefits in Patients Undergoing Complete Hepatectomy for Synchronous Colorectal Cancer With Liver and Lung Metastases

Clinical Management of Bowel Dysfunction After Low Anterior Resection for Rectal Cancer

Abstract The American Cancer Society estimated that 39,610 new cases of rectal cancer were diagnosed in the United States in 2015. Surgery is the primary treatment for rectal cancer, with the majority of patients undergoing sphincter-pr...

Trifluridine/Tipiracil: Old Drug, New Tricks

Patients Living Longer With Metastatic Colorectal Cancer

Assessment of Pathologic Response in Patients With Locally Advanced Rectal Cancer: Implications of the Park et al. Study

In a recent article in the Journal of Clinical Oncology, Park and colleagues reported on neoadjuvant treatment response as an early indicator of response for patients with rectal cancer. In this pair of articles, JADPRO contributors disc...

Locally Advanced Rectal Cancer: Does Assessment of Response After Neoadjuvant Chemoradiotherapy Impact Management?

Review of “Neoadjuvant treatment response as an early response indicator for patients with rectal cancer” by Park et al. (2012), Journal of Clinical Oncology, 15, 1770–1776. For another perspective on the Park et al. study, please see th...

Ziv-Aflibercept Use in Metastatic Colorectal Cancer

In August 2012, ziv-aflibercept (Zaltrap) was approved by the FDA for use in combination with FOLFIRI in certain oxaliplatin-refractory patients with mCRC. Read about the mechanism of action, key trials, and management strategies associa...

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST

In late 2012, regorafenib (Stivarga), a novel oral multikinase inhibitor, was approved by the FDA for certain previously treated patients with metastatic colorectal cancer. Even more recently, regorafenib received another approval for us...

Effects of Aspirin on Colorectal Cancer Related to Lynch Syndrome

This article is a review of “Long-term effects of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial” by Burn et al. (2011), Lancet, 378, 2081–2087. For another pers...

Aspirin and Decreased Colon Cancer Risk: Challenges Interpreting a Large Prospective Trial

In late 2011, Burn et al. published updated results on the CAPP2 trial in The Lancet. CAPP2 investigated the effects of daily aspirin on patients with Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer. The two relat...

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy

Case Study Ms. S.G., a 56-year-old woman with a poorly differentiated squamous cell carcinoma of the anal canal, American Joint Committee on Cancer stage III (T2, N1, M0), was initially diagnosed in December, 2007 at an outside institut...

An Early Postoperative Intraperitoneal Chemotherapy Policy for Patients With Colorectal Cancer

The focus of this article is a project that entailed creating and implementing a new policy on early postoperative intraperitoneal (IP) chemotherapy for patients with colorectal cancer (CRC). Colorectal cancer is a systemic malignancy th...

Rectal Cancer Incidence: Trends in Younger Patients

Biomarkers in Colorectal Cancer: Implications for Nursing Practice

Confirming the diagnosis of cancer has largely been the role of the pathologist, through examination and evaluation of tumor tissue. An adjunct to this process is the identification of a tumor marker, which can be found in tumor tissue o...

Collaborative Approach to Managing a 47-Year-Old Male with Stage IIB Rectosigmoid Colon Cancer and New Onset of Diabetes

Both cancer and diabetes are significant health-care challenges, and the coexistence of these diseases has been linked with increased mortality. To safely and effectively manage the patient with cancer and diabetes, the advanced practiti...